Newron Pharmaceuticals to Host 2024 Investor Day in New York City

Newron Pharmaceuticals will hold its 2024 Investor Day on June 25 in New York City. The event will take place at Convene, 530 Fifth Avenue, from 9:00-11:00 AM EDT. This gathering aims to provide insights into their ongoing developments, particularly focusing on evenamide, a treatment for chronic and treatment-resistant schizophrenia. Participants can join in person or via live webcast through the company's investor website.

Stefan Weber, CEO, and Ravi Anand, MD, Chief Medical Officer, will lead the event. Key opinion leaders, including Anthony Grace, Ph.D., John Kane, M.D., and Stephen R. Marder, M.D., will share novel insights and pre-clinical data on the efficacy of evenamide. Topics will cover the neurobiology of treatment-resistant cases and new treatment possibilities.

Newron aims to outline the roadmap for the U.S. and EU registration of evenamide. This compound is seen as a potential add-on therapy for schizophrenia, specifically targeting voltage-gated sodium channels to normalize glutamate release without broad impact on other CNS targets.